Autolus Therapeutics plc, a biopharmaceutical company listed on Nasdaq, announced on July 15, 2025, that its Board of Directors' compensation committee has granted stock option awards to 60 employees under the 2025 Inducement Plan. These options allow for the purchase of a total of 360,550 shares of common stock at an exercise price of $2.47 per share, matching the closing price on July 9, 2025. Each option comes with a ten-year term and vests over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years, contingent on ongoing employment with Autolus.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。